嵌合抗原受体
医学
肾细胞癌
免疫疗法
临床试验
免疫系统
恶性肿瘤
癌症研究
T细胞
抗原
肿瘤科
免疫学
内科学
作者
Yung Lyou,Tanya B. Dorff
出处
期刊:Kidney cancer
[IOS Press]
日期:2022-11-18
卷期号:6 (3): 159-168
摘要
Renal cell carcinoma (RCC) has long been found to be responsive to immunotherapy. While high dose interleukin-2 resulted in some durable remissions, this treatment has largely been replaced by immune checkpoint inhibitor therapy, due to the safer toxicity profile and emerging evidence for long term remissions. However, the majority of patients continue to face disease progression and death from metastatic RCC. Chimeric antigen receptor T-cells (CAR T) represent the next step in immunotherapy for this malignancy and hold promise for a higher rate of durable remissions. The realization of this therapeutic strategy for RCC will require identification of the best tumor antigen and T cell modifications and will depend on achieving remissions with an acceptable toxicity profile. This review summarizes current CAR T-cell treatment targets and clinical trials for metastatic RCC, highlighting the potential therapeutic impact as well as obstacles to successful development.
科研通智能强力驱动
Strongly Powered by AbleSci AI